North America Orthopedic Spine Devices Market Size, Share & Trends Analysis Report By Product (Spinal Fusion Devices, Vertebral Compression Fracture Treatment Devices, Non-fusion Devices), By End Use, By Region, And Segment Forecasts, 2025 - 2030

North America Orthopedic Spine Devices Market Size, Share & Trends Analysis Report By Product (Spinal Fusion Devices, Vertebral Compression Fracture Treatment Devices, Non-fusion Devices), By End Use, By Region, And Segment Forecasts, 2025 - 2030


Market Size & Trends

The North America orthopedic spine devices market size was estimated at USD 9.01 billion in 2024 and is projected to grow at a CAGR of 4.1% from 2025 to 2030. The rising incidence of road traffic crashes has significantly increased the number of Spinal Cord Injuries (SCIs). According to the National Spinal Cord Injury Statistical Center report published in 2023, approximately 18,000 new cases of SCIs occur annually in the U.S., which is about 54 incidents per 1 million people. The report also estimates that there are approximately 302,000 individuals living in the U.S. who have sustained an SCI.

Signs of aging such as weakening of bones due to excessive loss of bone mass, which is common between 25 and 54 years of age, and decreasing bone density, which becomes more prominent from 55 years & above, are expected to drive market demand. According to a 2019 publication from the National Library of Medicine, the 65-69 age bracket experienced the highest incidence of spinal cord fractures (69.2%), followed by a 50% rate in the 75-79 age group. The 70-74 age group most frequently received a diagnosis of central cord syndrome (43.8%, compared to 33.3% in the ≥80 years age group). Thus, the aging population is impelling the demand for orthopedic spine solutions. The Population Reference Bureau estimates that in 2022, the number of people in the U.S. aged 65 and older was 58 million, and it is expected to increase to 82 million by 2050.

The field of orthopedic surgery is constantly advancing with the continuous improvement of technologies. Enhanced versions of existing technologies are being developed to improve surgical outcomes and increase longevity. The tools, components, and instruments used in surgeries are consistently progressing. New titanium-based biocompatible or biomaterial-based screws and fixation systems have shown improved results with reduced chances of rejection over a longer period compared to previously used metal screws. Innovative technologies, including tissue grafting and the utilization of scaffolds and other tissue matrices for regenerating native tissue, have been effectively employed to enhance mobility and flexibility in recovered limbs. Matrices infused with growth factors are being utilized to promote better and faster healing of the tissue surrounding the injury.

Another driving force for the orthopedic spine devices market is increasing participation in sports & related events and the accompanying injuries. According to the report from Due North Consulting, Inc., approximately 242 million individuals in the U.S., which accounts for almost 80% of all Americans aged 6 and above, engaged in a sports or fitness activity in 2023. This marks a 2.2% rise from 2022, establishing it as the largest number of participants in a single year.

Increasing participation in sports leads to various injuries including cervical injuries. For instance, as per the National Library of Medicine report, the most common level of injury when a SCI occurs is cervical for four sports: hockey (81.5% cervical), skiing (81.1%), diving (98.2%), and American football (96.3%). In horseback riding, the largest proportion of injuries are cervical (46%), but thoracic (25.8%) and lumbo-sacral (24.4%) injuries are also prevalent. Snowboarding also has a significant risk for thoracic (27.6%) and thoraco-lumbar (28.9%) injuries.

North America Orthopedic Spine Devices Market Report Segmentation

This report forecasts revenue and volume growth at regional and country level and provides an analysis on industry trends in each of the sub segments from 2018 to 2030. For this study, Grand View Research, Inc. has segmented the North America orthopedic spine devices market report based on product, end use, and region:
  • Product Outlook (Revenue USD Million, 2018 - 2030)
  • Spinal Fusion Devices
Thoracic & Lumbar Fusion Devices

Cervical Fusion Devices
  • Vertebral Compression Fracture Treatment Devices
  • Non-fusion Devices
  • Spinal Implant
Spinal Fusion Implants

Spinal Non-fusion Implants
  • End Use Outlook (Revenue USD Million, 2018 - 2030)
  • Hospitals
  • Outpatient Facilities
  • Regional Outlook Revenue USD Million, 2018 - 2030)
  • North America
U.S.

Canada

Mexico

Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Study Design
1.2.2. Phase
1.2.3. Indication
1.2.4. Service Type
1.2.5. Sponsor
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Bottom-up Approach
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
1.12. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Europe Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing adoption of new technology in clinical research
3.2.1.2. Shift toward personalized medicine
3.2.1.3. Growing disease variation and prevalence
3.2.1.4. Growth in CRO market
3.2.2. Market Restraint Analysis
3.2.2.1. Regulations in new drug development
3.2.2.2. Pricing pressure
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. Analysis of total number of clinical trial studies conducted, by countries
3.3.4. Cost breakdown analysis for CRO's
3.3.5. Percent of outsourced vs in-house clinical trial categories
3.3.6. Cost breakdown analysis for CRO's by Phase I, II, & III
3.3.7. COVID-19 Impact Analysis
Chapter 4. Europe Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Europe Clinical Trials Market, Phase Movement Analysis
4.3. Europe Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
4.4. Phase I
4.4.1. Phase I Market, 2018 to 2030 (USD Million)
4.5. Phase II
4.5.1. Phase II Market, 2018 to 2030 (USD Million)
4.6. Phase III
4.6.1. Phase III Market, 2018 to 2030 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market, 2018 to 2030 (USD Million)
Chapter 5. Europe Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Europe Clinical Trials Market, Study Design Movement Analysis
5.3. Europe Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
5.4. Interventional studies
5.4.1. Interventional Studies Market, 2018 to 2030 (USD Million)
5.5. Observational studies
5.5.1. Observational Studies Market, 2018 to 2030 (USD Million)
5.6. Expanded access studies
5.6.1. Expanded Access Studies Market, 2018 to 2030 (USD Million)
Chapter 6. Europe Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Europe Clinical Trials Market, Indication Movement Analysis
6.3. Europe Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4. Autoimmune/inflammation
6.4.1. Autoimmune/Inflammation Market, 2018 to 2030 (USD Million)
6.4.2. Rheumatoid arthritis
6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
6.4.3. Multiple sclerosis
6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
6.4.4. Osteoarthritis
6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
6.4.5. Irritable Bowel Syndrome (IBS)
6.4.5.1. Irritable Bowel Syndrome (IBS) Market, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market, 2018 to 2030 (USD Million)
6.5. Pain Management
6.5.1. Pain Management Market, 2018 to 2030 (USD Million)
6.5.2. Chronic Pain
6.5.2.1. Chronic Pain Market, 2018 to 2030 (USD Million)
6.5.3. Acute Pain
6.5.3.1. Acute Pain Market, 2018 to 2030 (USD Million)
6.6. Oncology
6.6.1. Oncology Market, 2018 to 2030 (USD Million)
6.6.2. Blood Cancer
6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
6.6.3. Solid Tumors
6.6.3.1. Solid Tumors Market, 2018 to 2030 (USD Million)
6.6.4. Other
6.6.4.1. Other Market, 2018 to 2030 (USD Million)
6.7. CNS conditions
6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
6.7.2. Epilepsy
6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
6.7.3. Parkinson's Disease (PD)
6.7.3.1. Parkinson's Disease (PD) Market, 2018 to 2030 (USD Million)
6.7.4. Huntington's Disease
6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
6.7.5. Stroke
6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
6.7.6. Traumatic Brain Injury (TBI)
6.7.6.1. Traumatic Brain Injury (TBI) Market, 2018 to 2030 (USD Million)
6.7.7. Amyotrophic Lateral Sclerosis (ALS)
6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
6.7.8. Muscle Regeneration
6.7.8.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
6.7.9. Others
6.7.9.1. Other Market, 2018 to 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
6.9. Obesity
6.9.1. Obesity Market, 2018 to 2030 (USD Million)
6.10. Cardiovascular
6.10.1. Cardiovascular Market, 2018 to 2030 (USD Million)
6.11. Others
6.11.1. Others Market, 2018 to 2030 (USD Million)
Chapter 7. Europe Clinical Trials Market: Service Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Europe Clinical Trials Market, Service Type Movement Analysis
7.3. Europe Clinical Trials Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
7.4. Protocol Designing
7.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
7.5. Site Identification
7.5.1. Site Identification Market, 2018 to 2030 (USD Million)
7.6. Patient Recruitment
7.6.1. Patient Recruitment Market, 2018 to 2030 (USD Million)
7.7. Laboratory Services
7.7.1. Laboratory Services Market, 2018 to 2030 (USD Million)
7.8. Bioanalytical Testing Services
7.8.1. Bioanalytical Testing Services Market, 2018 to 2030 (USD Million)
7.9. Clinical Trial Data Management Services
7.9.1. Clinical Trial Data Management Services Market, 2018 to 2030 (USD Million)
7.10. Others
7.10.1. Others Market, 2018 to 2030 (USD Million)
Chapter 8. Europe Clinical Trials Market: Sponsor Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Europe Clinical Trials Market, Sponsor Movement Analysis
8.3. Europe Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
8.4. Pharmaceutical & biopharmaceutical companies
8.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.5. Medical device companies
8.5.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.6. Others
8.6.1. Others Market, 2018 to 2030 (USD Million)
Chapter 9. Europe Clinical Trials Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. Europe
9.3.1. Europe Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Competitive Scenario
9.3.2.3. Regulatory Framework
9.3.2.4. UK Market Estimates and Forecasts, 2018-2030
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Germany Market Estimates and Forecasts, 2018-2030
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. France Market Estimates and Forecasts, 2018-2030
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Italy Market Estimates and Forecasts, 2018-2030
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Spain Market Estimates and Forecasts, 2018-2030
9.3.7. Sweden
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Sweden Market Estimates and Forecasts, 2018-2030
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Denmark Market Estimates and Forecasts, 2018-2030
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Norway Market Estimates and Forecasts, 2018-2030
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Company Market Position Analysis, 2023
10.3. Company Profiles
10.3.1. IQVIA Holdings, Inc.,
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Parexel International Corporation
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. PPD, Inc.
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Syneos Health
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Eli Lilly and Company
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Novo Nordisk A/S
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Pfizer, Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Dr. Notghi Contract Research GmbH
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Charite Research Organisation GmbH
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Janssen Global Services, LLC
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. KFGN
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Clariness
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Invisio Clinical Studies Consulting GmbH
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings